Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients.

Avritscher EB, Shih YC, Sun CC, Gralla RJ, Grunberg SM, Xu Y, Elting LS.

J Support Oncol. 2010 Nov-Dec;8(6):242-51.

PMID:
21265391
2.

Clinical update on palonosetron in the management of chemotherapy-induced nausea and vomiting.

Celio L, Denaro A, Canova S, Gevorgyan A, Bajetta E.

Tumori. 2008 Jul-Aug;94(4):447-52. Review.

3.

Palonosetron (Aloxi) and dexamethasone for the prevention of acute and delayed nausea and vomiting in patients receiving multiple-day chemotherapy.

Musso M, Scalone R, Bonanno V, Crescimanno A, Polizzi V, Porretto F, Bianchini C, Perrone T.

Support Care Cancer. 2009 Feb;17(2):205-9. doi: 10.1007/s00520-008-0510-5. Epub 2008 Oct 7.

PMID:
18839220
4.
5.

Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.

Annemans L, Strens D, Lox E, Petit C, Malonne H.

Support Care Cancer. 2008 Aug;16(8):905-15. Epub 2007 Oct 27.

PMID:
17965891
6.

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.

Grunberg SM, Dugan M, Muss H, Wood M, Burdette-Radoux S, Weisberg T, Siebel M.

Support Care Cancer. 2009 May;17(5):589-94. doi: 10.1007/s00520-008-0535-9. Epub 2008 Nov 27.

PMID:
19037667
7.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
8.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
9.

Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.

Lorusso V, Spedicato A, Petrucelli L, Saracino V, Giampaglia M, Perrone T.

Support Care Cancer. 2009 Dec;17(12):1469-73. doi: 10.1007/s00520-009-0611-9. Epub 2009 Mar 18.

PMID:
19294429
11.

Is a dexamethasone-sparing strategy capable of preventing acute and delayed emesis caused by combined doxorubicin and paclitaxel for breast cancer? Analysis of a phase II trial.

Damian S, Celio L, De Benedictis E, Mariani P, Agustoni F, Ricchini F, De Braud F.

Oncology. 2013;84(6):371-7. doi: 10.1159/000348538. Epub 2013 May 22.

13.

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

Einhorn LH, Brames MJ, Dreicer R, Nichols CR, Cullen MT Jr, Bubalo J.

Support Care Cancer. 2007 Nov;15(11):1293-300. Epub 2007 Apr 14.

PMID:
17436025
14.

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.

Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.

PMID:
20206789
15.

A randomized study of aprepitant, ondansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately emetogenic chemotherapy.

Yeo W, Mo FK, Suen JJ, Ho WM, Chan SL, Lau W, Koh J, Yeung WK, Kwan WH, Lee KK, Mok TS, Poon AN, Lam KC, Hui EK, Zee B.

Breast Cancer Res Treat. 2009 Feb;113(3):529-35. doi: 10.1007/s10549-008-9957-9. Epub 2008 Mar 10.

PMID:
18327706
16.
17.

The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.

18.

Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.

Petru E, Andel J, Angleitner-Boubenizek L, Steger G, Bernhart M, Busch K, Gehmacher O, Hernler T, Kastner U, Lanz-Veit A, Pluschnigg U, Polachova J, Rohde M, Schiller L, Schramböck R, Stangl W, Thödtmann R, Zabernigg A.

Wien Med Wochenschr. 2008;158(5-6):169-73. doi: 10.1007/s10354-008-0515-1.

PMID:
18421559
19.

Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis.

Grunberg SM, Koeller JM.

Expert Opin Pharmacother. 2003 Dec;4(12):2297-303. Review.

PMID:
14640928
20.

Palonosetron in prevention of nausea and vomiting after highly emetogenic chemotherapy before haematopoietic stem cell transplantation-single center experience.

Rzepecki P, Pielichowski W, Oborska S, Barzal J, Mlot B.

Transplant Proc. 2009 Oct;41(8):3247-9. doi: 10.1016/j.transproceed.2009.07.071.

PMID:
19857722

Supplemental Content

Support Center